[Skip to Content]
[Skip to Content Landing]
Citations 0
June 15, 2005

Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(23):2860-2861. doi:10.1001/jama.293.23.2861-a

In Reply: We suspect that many physicians share the opinion of Drs Perret-Guillaume and Wahl that the utility of warfarin therapy that we used seemed too high, since physicians tend to be more averse to warfarin therapy than are patients with atrial fibrillation.1 As physicians, we need to take care that our own preferences (or our personal desire to avoid monitoring warfarin) do not usurp our patients’ preferences.

First Page Preview View Large
First page PDF preview
First page PDF preview